Nathan Sanicharane has been appointed as new business development manager for the chemicals sector at safety equipment specialist Draeger Safety UK.
Sanicharane has a Masters degree in Chemistry and has spent four years working in drugs development. He also has nearly five years’ experience in selling chromatography and specialist chemicals.
Draeger hires new business development manager
Nathan Sanicharane takes up the role
You may also like
Manufacturing
Why CAPA keeps failing and what strong organisations do differently
This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)
How a centralised qualification matrix reconciles vendor documentation, integrates risk-based verification and connects commissioning findings with deviation, CAPA and audit-ready evidence
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)
Documentation Specialist Snehal Godse explains why unit-level FAT and SAT leave critical multivendor interfaces unverified and proposes a risk-based framework to qualify product transfers, control signals, interlocks, sensors and shared utilities
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Research grade to GMP: how peptide quality requirements change as development progresses
This article presents a practical guide to matching peptide characterisation, impurity control, traceability and manufacturing oversight with rising regulatory expectations across preclinical and clinical development